Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

363 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Spatial heterogeneity and differential treatment response of acute myeloid leukemia and relapsed/refractory extramedullary disease after allogeneic hematopoietic cell transplantation.
Kunadt D, Herold S, Poitz D, Wagenführ L, Kretschmann T, Sockel K, Ruhnke L, Brückner S, Sommer U, Meier F, Röllig C, von Bonin M, Thiede C, Schetelig J, Bornhäuser M, Stölzel F. Kunadt D, et al. Among authors: herold s. Ther Adv Hematol. 2022 Aug 23;13:20406207221115005. doi: 10.1177/20406207221115005. eCollection 2022. Ther Adv Hematol. 2022. PMID: 36050938 Free PMC article.
Clonal architecture of del(5q) myelodysplastic syndromes: aberrant CD5 or CD7 expression within the myeloid progenitor compartment defines a subset with high clonal burden.
Oelschlaegel U, Alexander Röhnert M, Mohr B, Sockel K, Herold S, Ehninger G, Bornhäuser M, Thiede C, Platzbecker U. Oelschlaegel U, et al. Among authors: herold s. Leukemia. 2016 Feb;30(2):517-20. doi: 10.1038/leu.2015.158. Epub 2015 Jun 24. Leukemia. 2016. PMID: 26104659 Free PMC article. No abstract available.
TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation.
Middeke JM, Herold S, Rücker-Braun E, Berdel WE, Stelljes M, Kaufmann M, Schäfer-Eckart K, Baldus CD, Stuhlmann R, Ho AD, Einsele H, Rösler W, Serve H, Hänel M, Sohlbach K, Klesse C, Mohr B, Heidenreich F, Stölzel F, Röllig C, Platzbecker U, Ehninger G, Bornhäuser M, Thiede C, Schetelig J; Study Alliance Leukaemia (SAL). Middeke JM, et al. Among authors: herold s. Br J Haematol. 2016 Mar;172(6):914-22. doi: 10.1111/bjh.13912. Epub 2016 Jan 13. Br J Haematol. 2016. PMID: 26771088 Free article.
Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.
Göllner S, Oellerich T, Agrawal-Singh S, Schenk T, Klein HU, Rohde C, Pabst C, Sauer T, Lerdrup M, Tavor S, Stölzel F, Herold S, Ehninger G, Köhler G, Pan KT, Urlaub H, Serve H, Dugas M, Spiekermann K, Vick B, Jeremias I, Berdel WE, Hansen K, Zelent A, Wickenhauser C, Müller LP, Thiede C, Müller-Tidow C. Göllner S, et al. Among authors: herold s. Nat Med. 2017 Jan;23(1):69-78. doi: 10.1038/nm.4247. Epub 2016 Dec 12. Nat Med. 2017. PMID: 27941792 Free PMC article.
Donor cell leukemia: evidence for multiple preleukemic clones and parallel long term clonal evolution in donor and recipient.
Herold S, Kuhn M, Bonin MV, Stange T, Platzbecker U, Radke J, Lange T, Sockel K, Gutsche K, Schetelig J, Röllig C, Schuster C, Roeder I, Dahl A, Mohr B, Serve H, Brandts C, Ehninger G, Bornhäuser M, Thiede C. Herold S, et al. Leukemia. 2017 Jul;31(7):1637-1640. doi: 10.1038/leu.2017.104. Epub 2017 Mar 28. Leukemia. 2017. PMID: 28348390 No abstract available.
Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML.
Herold S, Sockel K, Sayehli C, Herbst R, Dührsen U, Oelschlägel U, Böttner A, Hindahl H, Kullmer J, Helas S, Sauer M, Mohr B, Mies A, Bornhäuser M, Ehninger G, Röllig C, Thiede C, Platzbecker U. Herold S, et al. Leukemia. 2017 Oct;31(10):2247-2251. doi: 10.1038/leu.2017.217. Epub 2017 Jul 10. Leukemia. 2017. PMID: 28690314 No abstract available.
Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations.
Garz AK, Wolf S, Grath S, Gaidzik V, Habringer S, Vick B, Rudelius M, Ziegenhain C, Herold S, Weickert MT, Smets M, Peschel C, Oostendorp RAJ, Bultmann S, Jeremias I, Thiede C, Döhner K, Keller U, Götze KS. Garz AK, et al. Among authors: herold s. Oncotarget. 2017 Oct 16;8(65):108738-108759. doi: 10.18632/oncotarget.21877. eCollection 2017 Dec 12. Oncotarget. 2017. PMID: 29312564 Free PMC article.
CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome.
Taube F, Georgi JA, Kramer M, Stasik S, Middeke JM, Röllig C, Krug U, Krämer A, Scholl S, Hochhaus A, Brümmendorf TH, Naumann R, Petzold A, Mulet-Lazaro R, Valk PJM, Steffen B, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW, Hänel M, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Herold S, Stölzel F, Sockel K, von Bonin M, Müller-Tidow C, Platzbecker U, Berdel WE, Serve H, Ehninger G, Bornhäuser M, Schetelig J, Thiede C; Study Alliance Leukemia (SAL). Taube F, et al. Among authors: herold s. Blood. 2022 Jan 6;139(1):87-103. doi: 10.1182/blood.2020009680. Blood. 2022. PMID: 34320176 Free article.
Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment.
Teipel R, Kroschinsky F, Kramer M, Kretschmann T, Egger-Heidrich K, Krüger T, Ruhnke L, Herold S, Stasik S, Sockel K, Middeke JM, Trautmann-Grill K, Bornhäuser M, Thiede C, von Bonin M. Teipel R, et al. Among authors: herold s. Blood Adv. 2022 Mar 22;6(6):1941-1946. doi: 10.1182/bloodadvances.2021005747. Blood Adv. 2022. PMID: 35008107 Free PMC article.
363 results